4.94
-0.36 (-6.79%)
Previous Close | 5.30 |
Open | 5.27 |
Volume | 323,433 |
Avg. Volume (3M) | 302,887 |
Market Cap | 111,216,056 |
Price / Sales | 110.21 |
Price / Book | 0.930 |
52 Weeks Range | |
Earnings Date | 11 Nov 2025 |
Operating Margin (TTM) | -15,818.10% |
Diluted EPS (TTM) | -7.22 |
Total Debt/Equity (MRQ) | 352.65% |
Current Ratio (MRQ) | 3.57 |
Operating Cash Flow (TTM) | -111.99 M |
Levered Free Cash Flow (TTM) | -76.86 M |
Return on Assets (TTM) | -48.76% |
Return on Equity (TTM) | -144.51% |
Market Trend
Short Term | Medium Term | ||
Industry | Biotechnology (US) | Mixed | Mixed |
Biotechnology (Global) | Mixed | Mixed | |
Stock | Adverum Biotechnologies, Inc. | Bullish | Bearish |
AIStockmoo Score
Analyst Consensus | 5.0 |
Insider Activity | NA |
Price Volatility | -2.0 |
Technical Moving Averages | 2.5 |
Technical Oscillators | 0.5 |
Average | 1.50 |
Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics. |
|
Sector | Healthcare |
Industry | Biotechnology |
Investment Style | Small Value |
% Held by Insiders | 13.10% |
% Held by Institutions | 79.44% |
Ownership
Name | Date | Shares Held |
---|---|---|
Principia Wealth Advisory, Llc | 30 Jun 2025 | 2,029,116 |
52 Weeks Range | ||
Price Target Range | ||
High | 33.00 (Chardan Capital, 568.02%) | Buy |
Median | 31.50 (537.65%) | |
Low | 30.00 (HC Wainwright & Co., 507.29%) | Buy |
Average | 31.50 (537.65%) | |
Total | 2 Buy | |
Avg. Price @ Call | 3.36 |
Firm | Date | Target Price | Call | Price @ Call |
---|---|---|---|---|
HC Wainwright & Co. | 23 Sep 2025 | 30.00 (507.29%) | Buy | 4.06 |
Chardan Capital | 13 Aug 2025 | 33.00 (568.02%) | Buy | 2.66 |
No data within this time range.
Date | Type | Details |
---|---|---|
22 Sep 2025 | Announcement | Adverum Biotechnologies Announces Completion of Screening for Pivotal Phase 3 ARTEMIS Trial of Ixo-vec for Wet Age-Related Macular Degeneration |
05 Sep 2025 | Announcement | Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
12 Aug 2025 | Announcement | Adverum Biotechnologies Reports Second Quarter 2025 Financial Results and Provides Pipeline Highlights |
06 Aug 2025 | Announcement | Adverum Biotechnologies to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2025 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |